[go: up one dir, main page]

MX2013014661A - Derivados de indolamina para el tratamiento de enfermedades del sistema nervioso central. - Google Patents

Derivados de indolamina para el tratamiento de enfermedades del sistema nervioso central.

Info

Publication number
MX2013014661A
MX2013014661A MX2013014661A MX2013014661A MX2013014661A MX 2013014661 A MX2013014661 A MX 2013014661A MX 2013014661 A MX2013014661 A MX 2013014661A MX 2013014661 A MX2013014661 A MX 2013014661A MX 2013014661 A MX2013014661 A MX 2013014661A
Authority
MX
Mexico
Prior art keywords
treatment
nervous system
central nervous
system diseases
indoleamine derivatives
Prior art date
Application number
MX2013014661A
Other languages
English (en)
Inventor
Marcin Kolaczkowski
Adam Bucki
Anna Wesolowska
Maciej Pawlowski
Monika Marcinkowska
Grzegorz Kazek
Marek Bednarski
Original Assignee
Adamed Sp Zoo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adamed Sp Zoo filed Critical Adamed Sp Zoo
Publication of MX2013014661A publication Critical patent/MX2013014661A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Derivados de indolamina de fórmula (lA), R1 representa bencilo no sustituido o sustituido con átomo de halógeno, -OH, o alquilo de C1-C3 fenilsulfonilo no sustituido o sustituido en el anillo fenilo con átomo de halógeno, -OH o alquilo de C1-C3; G1 representa fenoxialquilo, heteroariloxialquilo- o porción heterocicliloxialquil-piperazina; y sales y solvatos farmacéuticamente aceptables de los mismos; los compuestos pueden ser útiles para el tratamiento y/o la prevención de los trastornos de sistema nervioso central (Ver Formula).
MX2013014661A 2011-06-29 2012-06-28 Derivados de indolamina para el tratamiento de enfermedades del sistema nervioso central. MX2013014661A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL395469A PL395469A1 (pl) 2011-06-29 2011-06-29 Pochodne indoloamin do leczenia chorób osrodkowego ukladu nerwowego
PCT/IB2012/053309 WO2013001499A1 (en) 2011-06-29 2012-06-28 Indoleamine derivatives for the treatment of central nervous system diseases

Publications (1)

Publication Number Publication Date
MX2013014661A true MX2013014661A (es) 2014-03-27

Family

ID=46889380

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013014661A MX2013014661A (es) 2011-06-29 2012-06-28 Derivados de indolamina para el tratamiento de enfermedades del sistema nervioso central.

Country Status (13)

Country Link
US (1) US20140121216A1 (es)
EP (1) EP2726457A1 (es)
JP (1) JP2014518257A (es)
KR (1) KR20140040218A (es)
CN (1) CN103649048A (es)
AU (1) AU2012277358A1 (es)
BR (1) BR112013033603A2 (es)
CA (1) CA2838314A1 (es)
EA (1) EA201490182A1 (es)
IL (1) IL229791A0 (es)
MX (1) MX2013014661A (es)
PL (1) PL395469A1 (es)
WO (1) WO2013001499A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106749219A (zh) * 2015-11-20 2017-05-31 江苏恩华药业股份有限公司 一种内酰胺类衍生物及其应用
EP3530651A1 (en) * 2018-02-21 2019-08-28 Adamed sp. z o.o. Indole and benzimidazole derivatives as dual 5-ht2a and 5-ht6 receptor antagonists
CN116554145B (zh) * 2022-01-29 2025-06-03 江苏恩华药业股份有限公司 芳烷基-4-(1h)吲哚基哌嗪衍生物、其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0773942A1 (en) * 1994-07-26 1997-05-21 Pfizer Inc. 4-indole derivatives as serotonin agonists and antagonists
CN1100055C (zh) 1996-03-29 2003-01-29 杜菲尔国际开发有限公司 哌嗪和哌啶化合物
ZA9711376B (en) 1996-12-20 1998-07-21 Lundbeck & Co As H Indole or dihydroindole derivatives
AU736596B2 (en) 1997-07-25 2001-08-02 H. Lundbeck A/S Indole and 2,3-dihydroindole derivatives, their preparation and use
EP0900792B1 (en) 1997-09-02 2003-10-29 Duphar International Research B.V Piperazine and piperidine derivatives as 5-HT1A and dopamine D2-receptor (ant)agonists
WO1999055672A2 (en) 1998-04-29 1999-11-04 American Home Products Corporation Antipsychotic indolyl derivatives
AR027134A1 (es) 1999-12-30 2003-03-12 Lundbeck & Co As H Derivados de indol.
IL154685A0 (en) 2000-10-20 2003-09-17 Biovitrum Ab 2-,3-,4-, or 5-substituted-n1-(benzensulfonyl) indoles and their use in therapy
AU2005102A (en) * 2000-11-02 2002-05-15 Wyeth Corp 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
GB0227240D0 (en) 2002-11-21 2002-12-31 Glaxo Group Ltd Compounds
MX2009012506A (es) 2007-05-21 2009-12-09 Reviva Pharmaceuticals Inc Composiciones, sintesis, y metodos para utilizar agentes antipsicoticos atipicos basados en quinolinona.

Also Published As

Publication number Publication date
BR112013033603A2 (pt) 2016-09-06
JP2014518257A (ja) 2014-07-28
EA201490182A1 (ru) 2014-04-30
IL229791A0 (en) 2014-03-06
AU2012277358A1 (en) 2014-01-23
CA2838314A1 (en) 2013-01-03
KR20140040218A (ko) 2014-04-02
CN103649048A (zh) 2014-03-19
WO2013001499A1 (en) 2013-01-03
US20140121216A1 (en) 2014-05-01
PL395469A1 (pl) 2013-01-07
EP2726457A1 (en) 2014-05-07

Similar Documents

Publication Publication Date Title
PH12019501321B1 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders
CR20200286A (es) DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
MX2015012028A (es) Inhibidores de la ruta de quinurenina.
GEP201606532B (en) Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
IN2015DN01156A (es)
MX2012003539A (es) Derivados de indol como moduladores de los canales de calcio activados por la liberacion de calcio (crac).
MX356644B (es) Derivados de 2-fenilaminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2) para el tratamiento de la enfermedad de parkinson.
MX339759B (es) Compuesto para el tratamiento/prevencion de enfermedades inflamatorias oculares.
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
GEP20166474B (en) Pyrazolospiroketone derivatives for use as acetyl-coa carboxylase inhibitors
GEP20156351B (en) Glucagon receptor modulator
MX341565B (es) 3-amino-piridinas como agonistas de receptor de acido biliar acoplado a proteina g1 (gpbar1).
TW200736233A (en) Cyclohexyl piperazinyl methanone derivatives
NZ600874A (en) Fluorinated derivatives of deferiprone
GEP20186878B (en) 2,6-substituted purine derivatives and their use in the treatment of proliferative disorders
SG195257A1 (en) Anti-thrombotic compounds
MX2012007582A (es) Compuestos de 4-fenoxi-nicotinamida o 4-fenoxi-pirimidina-5-carbox amida.
TW200738651A (en) Cyclohexyl sulfonamide derivatives
MX2012002528A (es) Agente terapeutico para trastornos del estado de animo.
PH12015500012B1 (en) Benzodioxole derivative and preparation method and use thereof
MX2013002956A (es) Arilsulfonamidas para el tratamiento de enfermedades del sistema nervioso central.
MX2013014661A (es) Derivados de indolamina para el tratamiento de enfermedades del sistema nervioso central.
PH12012501142A1 (en) Heterocyclic sulfonamide derivatives
MX2014005538A (es) 1-piridazinil-hidroxiimino-3-fenil-propanos como agonistas de proteina g-receptor acoplado a acido biliar 1 (gpbar1).
DE602008002598D1 (en) Cyclohexylderivate

Legal Events

Date Code Title Description
FA Abandonment or withdrawal